Best Fit Profiles
- longevity protocols as a more bioavailable alternative to resveratrol
SIRT1 activation and metabolic support
Pterostilbene
Pterostilbene is a dimethyl ether analog of resveratrol with greater bioavailability and longer half-life. Preclinical data is promising for SIRT1 activation, metabolic effects, and neuroprotection. Human trial data is very limited.
Evidence Level C
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Promising preclinical data; human evidence is sparse and cannot confirm clinical benefit
- Safety
- Low Risk
One human trial noted LDL elevation at higher doses (250 mg); use with caution if cardiovascular risk is elevated.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 50-150 mg
- Timing
- With meals
- Protocol Duration in Studies
- 12 weeks minimum; longer data needed
Often stacked with resveratrol or NMN in longevity protocols; evidence for combination is anecdotal.